Prognostic role of blood eosinophils in acute exacerbations of chronic obstructive pulmonary disease: systematic review and meta-analysis
Abstract
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a major cause of hospitalization and mortality worldwide. While blood eosinophils have been suggested as a prognostic biomarker of COPD, their predictive value in AECOPD remains uncertain. This meta-analysis aims to evaluate the prognostic role of blood eosinophil counts in predicting mortality and hospital readmission in these patients. A systematic review and meta-analysis were conducted according to PRISMA guidelines. We included studies that evaluated the prognostic role of blood eosinophils in AECOPD, with predefined cut-offs. Data on mortality and readmission rates were extracted, and statistical analyses were performed to assess sensitivity, specificity, and likelihood ratios. A total of 14 studies with 23,625 patients were included. High blood eosinophil counts during AECOPD hospitalization had low sensitivity (28.1%) and specificity (66.2%) in predicting 12-month mortality and readmission. Positive and negative likelihood ratios were also suboptimal, with values of 0.8 and 1.1, respectively. Sensitivity analyses, including only high-quality studies, confirmed these findings. The results suggest that blood eosinophil counts have limited prognostic value in predicting mortality and readmission in AECOPD patients. The variability in eosinophil cut-offs and lack of consistent data across studies contribute to this limitation. Further large-scale prospective studies are needed to clarify the role of eosinophils as a prognostic marker in AECOPD. Consequently, routine measurement of blood eosinophils during acute exacerbations may not be warranted for prognostic purposes.
References
- Zhang HL, Tan M, Qiu AM, et al. Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulm Med 2017;17:196. DOI: https://doi.org/10.1186/s12890-017-0541-0
- Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology 2016;21:1152-65. DOI: https://doi.org/10.1111/resp.12780
- Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax 2019;74:439-46. DOI: https://doi.org/10.1136/thoraxjnl-2018-211855
- Brusselle G, Pavord ID, Landis S, et al. Blood eosinophil levels as a biomarker in COPD. Respir Med 2018;138:21-31. DOI: https://doi.org/10.1016/j.rmed.2018.03.016
- Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J 2019;54:1900651. DOI: https://doi.org/10.1183/13993003.00651-2019
- Emami Ardestani M, Alavi-Naeini N. Evaluation of the relationship of neutrophil-to lymphocyte ratio and platelet-to-lymphocyte ratio with in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease. Clin Respir J 2021;15:382-8. DOI: https://doi.org/10.1111/crj.13312
- Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. DOI: https://doi.org/10.1136/bmj.n71
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000;283:2008-12. DOI: https://doi.org/10.1001/jama.283.15.2008
- Wells GA, Wells G, Shea B, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014.
- Zwinderman AH, Bossuyt PM. We should not pool diagnostic likelihood ratios in systematic reviews. Stat Med 2008;27:687-97. DOI: https://doi.org/10.1002/sim.2992
- Kostikas K, Papathanasiou E, Papaioannou AI, et al. Blood eosinophils as predictor of outcomes in patients hospitalized for COPD exacerbations: a prospective observational study, Biomarkers 2021;4:354-62. DOI: https://doi.org/10.1080/1354750X.2021.1903998
- Martínez-Gestoso S, García-Sanz MT, Calvo-Álvarez U, et al. Variability of blood eosinophil count and prognosis of COPD exacerbations. Ann Med 2021;53:1152-8. DOI: https://doi.org/10.1080/07853890.2021.1949489
- Peng J, Yu Q, Fan S, et al. High blood eosinophil and YKL-40 levels, as well as low CXCL9 levels, are associated with increased readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2021;16:795-806. DOI: https://doi.org/10.2147/COPD.S294968
- Bélanger M, Couillard S, Courteau J, et al. Eosinophil counts in first COPD hospitalizations: a comparison of health service utilization. Int J Chron Obstruct Pulmon Dis 2018;13:3045-54. DOI: https://doi.org/10.2147/COPD.S170743
- Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest 2017;151:366-73. DOI: https://doi.org/10.1016/j.chest.2016.10.003
- Wu CW, Lan CC, Hsieh PC, et al. Role of peripheral eosinophilia in acute exacerbation of chronic obstructive pulmonary disease. World J Clin Cases 2020;8:2727-37. DOI: https://doi.org/10.12998/wjcc.v8.i13.2727
- Bafadhel M, Greening NJ, Harvey Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest 2016;150:320-8. DOI: https://doi.org/10.1016/j.chest.2016.01.026
- Ko FWS, Chan KP, Ngai J, et al. Blood eosinophil count as a predictor of hospital length of stay in COPD exacerbations. Respirology 2020;25:259-66. DOI: https://doi.org/10.1111/resp.13660
- Russell R, Beer S, Pavord ID, et al. The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2019;14:971-7. DOI: https://doi.org/10.2147/COPD.S190085
- Ruiying W, Zhaoyun, Jianying X. Clinical features and three-year prognosis of AECOPD patients with different levels of blood eosinophils. Heart Lung 2022;56:29-39. DOI: https://doi.org/10.1016/j.hrtlng.2022.05.012
- Pu J, Yi Q, Luo Y, et al. Blood eosinophils and clinical outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. Int J Chron Obstruct Pulmon Dis 2023;18:169-79. DOI: https://doi.org/10.2147/COPD.S396311
- Hegewald MJ, Horne BD, Trudo F, et al. Blood eosinophil count and hospital readmission in patients with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2020;15:2629-41. DOI: https://doi.org/10.2147/COPD.S251115
- Hasegawa K, Camargo CA Jr. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology 2016;21:761-4. DOI: https://doi.org/10.1111/resp.12724
- Cui Y, Zhan Z, Zeng Z, et al. Blood eosinophils and clinical outcomes in patients with acute exacerbation of chronic obstructive pulmonary disease: a propensity score matching analysis of real-world data in China. Front Med 2021;8:653777. DOI: https://doi.org/10.3389/fmed.2021.653777
- Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018;141:2037-47.e10.
- Kim VL, Coombs NA, Staples KJ, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J 2017;50:1700853. DOI: https://doi.org/10.1183/13993003.00853-2017
- Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in COPD: the Copenhagen general population study. Am J Respir Crit Care Med 2016;193:965-74. DOI: https://doi.org/10.1164/rccm.201509-1869OC
- Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71. DOI: https://doi.org/10.1164/rccm.201104-0597OC
- Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3:435-42. DOI: https://doi.org/10.1016/S2213-2600(15)00106-X
- Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:523-5. DOI: https://doi.org/10.1164/rccm.201502-0235LE
- Håkansson KEJ, Ulrik CS, Godtfredsen NS, et al. High suPAR and low blood eosinophil count are risk factors for hospital readmission and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis 2020;15:733-43. DOI: https://doi.org/10.2147/COPD.S229904
- Reddel HK, Gerhardsson de Verdier M, Agustí A, et al. Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res 2019;5:00036-2018. DOI: https://doi.org/10.1183/23120541.00036-2018
- Woodruff PG, Agusti A, Roche N, et al. Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 2015;385:1789-98. DOI: https://doi.org/10.1016/S0140-6736(15)60693-6
- Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014;2:891-901. DOI: https://doi.org/10.1016/S2213-2600(14)70187-0
- Mao Y, Qian Y, Sun X, Li N, Huang H. Eosinopenia predicting long-term mortality in hospitalized acute exacerbation of COPD patients with community-acquired pneumonia-a retrospective analysis. Int J Chron Obstruct Pulmon Dis 2021;16:3551-9. DOI: https://doi.org/10.2147/COPD.S347948
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2025 The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.